主讲：美国达特茅斯Thayer工程学院 Brian Pogue教授
专家简介：Brian W. Pogue, Ph.D. is the MacLean Professor of Engineering at Dartmouth in Hanover, New Hampshire USA, and is Adjunct Professor of Surgery at the Geisel School of Medicine. His Ph.D. is in Medical/Nuclear Physics from McMaster University, Canada. He was Research Fellow at the Wellman Center for Photomedicine, Mass. General Hospital & Harvard Medical School. At Dartmouth since 1996, he works in the area of Optics in Medicine, with a focus on novel imaging systems for characterizing cancer and tracking therapy. He was Dean of Graduate Studies at Dartmouth from 2008-2012 and is now Director of MS and PhD Programs in Engineering Science & Medical Physics. He has published over 350 peer-reviewed papers and >400 conference papers in cancer therapy, surgery, medicine, medical oncology, and radiotherapy. His research is funded by the NIH through two Program Project grants as well as several individual R01 grants. He is the Editor-in-Chief of the Journal of Biomedical Optics published by SPIE and is a Fellow of the International Society for Optics and Photonics (SPIE), the Optical Society of America (OSA) and the American Institute of Medical and Biological Engineers (AIMBE). He recently founded the startup company DoseOptics LLC, making the world’s first camera to image radiotherapy dose delivery.
报告摘要：The process of imaging medical treatments today is dominated by optical devices which are used at the point of care, in settings such as surgery and endoscopy, and the scale of optical imaging systems is much larger than radiological systems. These procedure-based tools are used to capture unique contrast features that help guide medical decisions about tissue removal and tissue response to therapy. Major advances have occurred in camera systems in the past decade, such as image-guided spectroscopy during surgery, as well as surgical guidance navigation tools, and now radiologic guidance tools. Molecular guidance for surgical imaging has been progressing and both new camera systems are available and molecular probes are being advanced into human trials. As such, the ability to guide surgery with fluorescence from molecular probes to metabolism or immunological expression is now possible. In radiation therapy, optical emissions during therapy from Cherenkov light, have been shown to provide a direct way to image radiation dose as well. This Cherenkov signal has been shown to be useful in soft tissue radiotherapy. Translation through a startup company, DoseOptics LLC, will be highlighted in which this pathway has enabled testing and deployment of a fundamentally new technology to image radiation dose delivery in real time. Additionally, use of Cherenkov light to excite molecular probes or photodynamic therapy action is also possible and these advances will be outlined.